A new method to deliver agents in the brain to study and modify neural circuits
AnteroTag, a Novel Method for Trans-Synaptic Delivery of Active Agents to Map and Modify Anterograde Populations
This study is testing a new way to help deliver treatments directly to specific parts of the brain using a special protein tag called AnteroTag, and it's designed for people interested in improving therapies for brain conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10258693 on NIH RePORTER |
What this research studies
This research focuses on developing a novel protein tag called AnteroTag, which aims to enhance the delivery of therapeutic agents to specific areas in the brain. By utilizing the natural processes of neurotransmission, AnteroTag will target synaptic vesicles to ensure effective release and action of these agents. The project will rigorously test this method using a well-established brain circuit model in mice, employing advanced techniques such as microscopy and in vivo imaging to assess its effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with neurological conditions that could benefit from targeted brain therapies.
Not a fit: Patients with conditions unrelated to brain disorders or those who do not meet specific eligibility criteria for the study may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for treating brain disorders by enabling precise manipulation of neural circuits.
How similar studies have performed: While the approach of using targeted delivery methods in neuroscience is being explored, the specific AnteroTag method represents a novel strategy that has not been extensively tested in prior studies.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Williams, Michael Roland — Michigan State University
- Study coordinator: Williams, Michael Roland
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.